Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

BACKGROUND: Patients with recurrent glioblastoma (rGB) have a poor prognosis with a median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous administration of programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors has low activity in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Duerinck, Johnny, Schwarze, Julia Katharina, Awada, Gil, Tijtgat, Jens, Vaeyens, Freya, Bertels, Cleo, Geens, Wietse, Klein, Samuel, Seynaeve, Laura, Cras, Louise, D’Haene, Nicky, Michotte, Alex, Caljon, Ben, Salmon, Isabelle, Bruneau, Michaël, Kockx, Mark, Van Dooren, Sonia, Vanbinst, Anne-Marie, Everaert, Hendrik, Forsyth, Ramses, Neyns, Bart
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8231061/
https://ncbi.nlm.nih.gov/pubmed/34168003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002296
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados